[
  {
    "ts": null,
    "headline": "Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know",
    "summary": "Moderna (MRNA) concluded the recent trading session at $28.38, signifying a +2.83% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=5fa57cacc7a01828e62b99a1fb5c5c44c4cb4aa94099a76ff42f7d03fef3e121",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759441805,
      "headline": "Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know",
      "id": 136960771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) concluded the recent trading session at $28.38, signifying a +2.83% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=5fa57cacc7a01828e62b99a1fb5c5c44c4cb4aa94099a76ff42f7d03fef3e121"
    }
  },
  {
    "ts": null,
    "headline": "Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?",
    "summary": "Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.",
    "url": "https://finnhub.io/api/news?id=8d687c97057e476f96c06879559a7b7f894130bb1ceea45fbd112b66696ef077",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759415520,
      "headline": "Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?",
      "id": 136960113,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.",
      "url": "https://finnhub.io/api/news?id=8d687c97057e476f96c06879559a7b7f894130bb1ceea45fbd112b66696ef077"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average",
    "summary": "When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?",
    "url": "https://finnhub.io/api/news?id=e5f44821417dcca1aba404f2c0748bf48fc93480c0aba6fe051fa5ca57f3f452",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759411801,
      "headline": "Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average",
      "id": 136960773,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?",
      "url": "https://finnhub.io/api/news?id=e5f44821417dcca1aba404f2c0748bf48fc93480c0aba6fe051fa5ca57f3f452"
    }
  },
  {
    "ts": null,
    "headline": "Brookline Reaffirms Price Target for Moderna (MRNA) After Strong mRNA-1283 Vaccine Results",
    "summary": "Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc. (NASDAQ:MRNA)’s refrigerator-stable COVID-19 vaccine, Brookline Capital Markets reaffirmed its Buy rating and $198 price target for the company on September 23. According to the new data, mNEXSPIKE/mRNA-1283 increased neutralizing antibodies against the LP.8.1 variant by an average […]",
    "url": "https://finnhub.io/api/news?id=848f8052c37242aa8c5ef7de24818f6c1d98c527a7e4adc0f8adb24b3828f32f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759383341,
      "headline": "Brookline Reaffirms Price Target for Moderna (MRNA) After Strong mRNA-1283 Vaccine Results",
      "id": 136955743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc. (NASDAQ:MRNA)’s refrigerator-stable COVID-19 vaccine, Brookline Capital Markets reaffirmed its Buy rating and $198 price target for the company on September 23. According to the new data, mNEXSPIKE/mRNA-1283 increased neutralizing antibodies against the LP.8.1 variant by an average […]",
      "url": "https://finnhub.io/api/news?id=848f8052c37242aa8c5ef7de24818f6c1d98c527a7e4adc0f8adb24b3828f32f"
    }
  }
]